- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03427229
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
Randomized Clinical Trial: Single Versus Multiple-infusion Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
Fecal microbiota transplantation (FMT) is acknowledged as a highly effective treatment for recurrent Clostridium difficile infection (CDI). Usually single fecal infusion achieves satisfactory cure rates of recurrent CDI). However, several retrospective studies show that severe clinical picture of recurrent CDI is a risk factor for the failure of single-infusion FMT, suggesting that multiple fecal infusions are required to cure this condition.
This is an open-label randomized clinical trial aiming to assess if multiple-infusion FMT is more effective than single-infusion FMT in curing severe CDI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fecal microbiota transplantation (FMT) is acknowledged as a highly effective treatment for recurrent Clostridium difficile infection (CDI). Usually single fecal infusion achieves satisfactory cure rates of recurrent CDI). However, several retrospective studies show that severe clinical picture of recurrent CDI is a risk factor for the failure of single-infusion FMT, suggesting that multiple fecal infusions are required to cure this condition.
This is an open-label randomized clinical trial aiming to assess if multiple-infusion FMT is more effective than single-infusion FMT in curing severe CDI
The investigators' study is an open-label randomized controlled trial, enrolling patients with recurrent and refractory C. difficile infection with a severe clinical picture of the disease.
At enrollment, C. difficile infection is defined as diarrhoea (at least 3 loose or watery stools per day for 2 or more consecutive days, or at least 8 loose stools in 48 hours) and positivity in the C. difficile toxin stool test.
Recurrent C. difficile infection is meant as the reappearance of clinical symptoms and positivity of C. difficile toxin test within 8 weeks after the end of the previous therapy.
Refractory CDI is defined as CDI unresponsive to the antimicrobial treatment, namely persistence of diarrhoea with CD toxin positive or persistent diarrhoea with toxin negative in the absence of other possible causes of diarrhoea (e.g. IBS, IBD, non-CDI antibiotic-associated diarrhea) Severe CDI is defined, according to the latest ESCMID guidelines, as: Episode of CDI with one or more specific clinical (fever, haemodynamic instability, respiratory failure which needs mechanical ventilation, signs and symptoms of peritonitis, signs and symptoms of colonic ileus), laboratory (marked leukocytosis, rise in serum creatinine and lactate, marked decrease of serum albumin), radiological (colon distension, colonic wall thickening) or endoscopic (pseudomembranous colitis), symptoms and signs of severe colitis or complicated course of disease.
Patients' stool are screened for detection of parasites and enteric bacterial pathogens to exclude other infective pathogens. Patients with former colectomy, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), viral hepatitis, AIDS or syphilis will be excluded.
Patients are instructed and invited to signal recurrent symptoms and diarrhea after treatment. Monthly clinical and lab checks are performed for a period of 2 months after the treatment.
Treatment procedures:
All patients start therapy with vancomycin for 3 days before of stratification, with random allocation (1 to 1, through statistical software) to one of the two treatment schemes: 1) single-infusion FMT by colonoscopy, with the infusion in the cecum - through the biopsy channel - of 60-120 gr (depending on production) of donated feces, obtained from the donor within 6 hours from transplantation, and manually homogenized in 100/200 ml of physiological solution; colonoscopy will be performed by an expert endoscopist; preparation for colonoscopy (four liters of a solution with saline laxatives) will be provided 2) multiple-infusion FMT (with the same protocol of the other arm, but with repeated fecal infusions).
All patient will be instructed on hygiene rules to be followed at the patient's domicile to avoid re-infections at home. Stool donors will be selected following recommendations from the European FMT Working Group Consensus Conference.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Recurrent C. difficile infection (identified by positivity of C. difficile toxin in stools) with severe clinical picture (defined by the ESCMID Guidelines published in 2014 - Debast et al, Clin Microbiol Infect 2014)
- Possibility to undergo standard antimicrobial therapy for recurrent C. difficile infection Approval of informed consent
- Possibility to undergo protocol diagnostic and therapeutic procedures
- Stool negativity for parasites
- Stool negativity for Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic Escherichia coli and other microorganisms except for C. difficile
- Blood negativity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL).
Exclusion Criteria:
- Subjects <18 years old
- Prior colectomy
- Negativity of C. difficile toxin in stools
- Mild clinical picture of C. difficile infection
- High risk of post-colonoscopy complications
- Other main gastrointestinal diseases (es. Crohn's disease or ulcerative colitis)
- Stool positivity for parasites
- Stool positivity for Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic Escherichia coli and other microorganisms except for C. difficile
- Blood positivity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL).
- Pregnancy or breastfeeding.
- Inability to follow protocol procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Multiple-infusion FMT
Repeated fecal infusions by colonoscopy.
Before FMT, vancomycin is administered in all patients for 3 days
|
Vancomycin is administered in all patients for 3 days before randomization.
Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
Patients will receive multiple fecal infusions by colonoscopy
|
ACTIVE_COMPARATOR: Single-infusion FMT
Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
|
Vancomycin is administered in all patients for 3 days before randomization.
Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
Patients will receive a single fecal infusion by colonoscopy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure of C. difficile infection
Time Frame: 8 weeks
|
Disappearance of C. difficile-associated diarrhea
|
8 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Enterocolitis
- Infections
- Colitis
- Clostridium Infections
- Enterocolitis, Pseudomembranous
- Anti-Infective Agents
- Anti-Bacterial Agents
- Vancomycin
Other Study ID Numbers
- 1206132017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
Hamilton Health Sciences CorporationRecruitingClostridium Difficile Diarrhea | Clostridium Difficile ColonizationCanada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
-
University of AlbertaTerminatedClostridium DifficileCanada
-
McMaster UniversitySt. Joseph's Healthcare HamiltonTerminated
-
Astellas Pharma Europe Ltd.Merck Sharp & Dohme LLCCompletedClostridium DifficileGreece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
-
Microbiome Health Research InstituteBrown University; Tufts Medical Center; Indiana University; Edward HospitalTerminatedClostridium DifficileUnited States
-
Seres Therapeutics, Inc.Syneos HealthCompletedClostridium DifficileUnited States
Clinical Trials on Vancomycin (before randomization)
-
Catholic University of the Sacred HeartCompletedClostridium DifficileItaly
-
University of ChileFondo Nacional de Desarrollo Científico y Tecnológico, ChileTerminatedMetabolic SyndromeChile
-
Massachusetts General HospitalVedanta Biosciences, Inc.Recruiting
-
Intergroupe Francophone de Cancerologie ThoraciqueRecruiting
-
Tze-Woei TanBoston University; University of UtahNot yet recruitingEnd Stage Renal FailureUnited States
-
Pirogov Russian National Research Medical UniversityRecruitingVenous ThromboembolismRussian Federation
-
Odense University HospitalUniversity of Southern DenmarkCompletedPain | Physical ActivityDenmark
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Kenyatta National... and other collaboratorsCompletedHIV | Adolescent BehaviorKenya
-
Laval UniversityWithdrawn
-
Case Western Reserve UniversityCystic Fibrosis FoundationWithdrawnCystic Fibrosis | Methicillin-resistant Staphylococcus AureusUnited States